Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sino Biopharmaceutical ( (HK:1177) ) has shared an announcement.
Sino Biopharmaceutical Limited announced that its subsidiary, LaNova Medicines, has received IND approval from the US FDA for LM-350, an innovative ADC targeting CDH17. This drug shows promise in treating various gastrointestinal tumors, particularly colorectal cancer, and highlights the company’s strong pipeline of ADC products in clinical and preclinical stages, potentially enhancing its industry positioning.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company in the pharmaceutical industry, focusing on the development and commercialization of innovative drugs. Its primary products include antibody-drug conjugates (ADCs), with a significant market focus on addressing unmet clinical needs in cancer treatment.
Average Trading Volume: 155,055,864
Technical Sentiment Signal: Buy
Current Market Cap: HK$119.6B
For an in-depth examination of 1177 stock, go to TipRanks’ Overview page.